[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558129":3},{"organization":4,"outcomesModule":7,"designInfo":35,"detailedDescription":38,"studyPopulation":39,"armGroups":40,"interventions":53,"overallOfficials":71,"centralContacts":78,"locations":84,"responsibleParty":101,"collaborators":103,"id":107,"slug":108,"hasResults":109,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":116,"minAge":117,"maxAge":11,"enrollmentInfo":118,"targetDuration":11,"studyType":121,"phases":11,"briefSummary":122,"conditions":123,"keywords":11,"overallStatus":86,"whyStopped":11,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":22,"otherOutcomes":11},[9,13,15,17,20],{"measure":10,"description":11,"timeFrame":12},"Area under the curve (AUC) of plasma amyloid-beta 42\u002F40 in predicting amyloid PET status",null,"Baseline",{"measure":14,"description":11,"timeFrame":12},"Area under the curve (AUC) of plasma %p-tau217 in predicting amyloid PET status",{"measure":16,"description":11,"timeFrame":12},"Area under the curve (AUC) of plasma p-tau217 in predicting tau PET status",{"measure":18,"description":11,"timeFrame":19},"Area under the curve (AUC) of plasma %p-tau217 in predicting clinical diagnosis","Baseline, 1 year, 2 years, 3 years, 4 years, 5 years",{"measure":21,"description":11,"timeFrame":19},"Area under the curve (AUC) of plasma amyloid-beta 42\u002F40 in predicting clinical diagnosis",[23,25,27,29,31,33],{"measure":24,"description":11,"timeFrame":12},"Area under the curve (AUC) of plasma p-tau205 in predicting tau PET status",{"measure":26,"description":11,"timeFrame":12},"Area under the curve (AUC) of plasma neurofilament light in predicting tau PET status",{"measure":28,"description":11,"timeFrame":19},"Area under the curve (AUC) of plasma %p-tau205 in predicting clinical diagnosis",{"measure":30,"description":11,"timeFrame":19},"Area under the curve (AUC) of plasma neurofilament light in predicting clinical diagnosis",{"measure":32,"description":11,"timeFrame":12},"Area under the curve (AUC) of plasma eMTBR-243 in predicting tau PET status",{"measure":34,"description":11,"timeFrame":19},"Area under the curve (AUC) of plasma eMTBR-243 in predicting clinical diagnosis",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":36,"timePerspective":37,"maskingInfo":11},"CASE_CONTROL","PROSPECTIVE","All participants who are eligible and provide informed consent will complete an initial study visit, which includes a research blood collection and cognitive assessments. Depending on the results of the cognitive assessments, participants will complete follow-up visits annually or biennially for additional cognitive testing, research blood collections, and potential clinical testing for Alzheimer's disease as determined by the participant's medical provider.","All participants who completed our prior study, the Study to Evaluate Amyloid in Blood and Imaging Related to Dementia (SEABIRD, NCT03899844), will be invited to join SUNBIRD. We will also recruit approximately 1000 new participants from Washington University and Barnes-Jewish Hospital affiliated clinics in the greater St. Louis metropolitan area.",[41,47],{"label":42,"type":11,"description":43,"interventionNames":44},"Cognitively normal","Participants without symptoms of cognitive impairment will be followed up annually for potential cognitive changes, and will complete additional blood collections every two years.",[45,46],"Other: Research blood collection","Other: Cognitive assessments",{"label":48,"type":11,"description":49,"interventionNames":50},"Cognitively impaired","For participants with symptoms of cognitive impairment, their medical providers will review the results of the research cognitive assessments and determine whether further testing (a clinical tau PET scan and choice of an amyloid PET, cerebrospinal fluid, or blood clinical test for amyloid plaques) is needed. Symptomatic participants will be followed up annually for research blood collections and cognitive assessments.",[51,52,45,46],"Diagnostic Test: Clinical tau PET","Diagnostic Test: Clinical amyloid test",[54,59,63,67],{"type":55,"name":56,"description":57,"armGroupLabels":58,"otherNames":11},"DIAGNOSTIC_TEST","Clinical tau PET","Tau PET (flortaucipir)",[48],{"type":55,"name":60,"description":61,"armGroupLabels":62,"otherNames":11},"Clinical amyloid test","Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test",[48],{"type":6,"name":64,"description":65,"armGroupLabels":66,"otherNames":11},"Research blood collection","Research blood assays for amyloid, tau, and neurodegeneration",[48,42],{"type":6,"name":68,"description":69,"armGroupLabels":70,"otherNames":11},"Cognitive assessments","Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)",[48,42],[72,75],{"name":73,"affiliation":5,"role":74},"Randall Bateman, MD","PRINCIPAL_INVESTIGATOR",{"name":76,"affiliation":5,"role":77},"David Carr, MD","STUDY_DIRECTOR",[79],{"name":80,"role":81,"phone":82,"phoneExt":11,"email":83},"Lisa Soke","CONTACT","314-747-4857","sunbirdstudy@wustl.edu",[85],{"facility":5,"status":86,"city":87,"state":88,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":97,"contacts":98},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":93,"coordinates":94},"Point",[95,96],-90.19789,38.62727,{"lat":96,"lon":95},[99,100],{"name":80,"role":81,"phone":82,"phoneExt":11,"email":83},{"name":73,"role":74,"phone":11,"phoneExt":11,"email":11},{"type":102,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[104],{"name":105,"class":106},"National Institute on Aging (NIA)","NIH","100558129","study-to-understand-novel-biomarkers-in-researching-dementia-100558129",false,"NCT06547099","Study to Understand Novel Biomarkers in Researching Dementia","Blood Amyloid, Tau, and Neurodegeneration Biomarkers and Prediction of Clinical Onset, Cognitive Decline, and Dementia Diagnosis","SUNBIRD","Inclusion Criteria:\n\n* At least 60 years of age\n* 80% of the newly enrolled clinic-based cohort will have symptoms of forgetfulness, mild cognitive impairment, mild dementia, or Alzheimer's disease as determined by their medical chart and\u002For provider\n* All SEABIRD participants will be invited to participate regardless of their cognitive status\n\nExclusion Criteria:\n\n* Unable to perform one or more basic activities of daily living (eating, bathing, dressing, ambulating, toileting) due to cognitive impairment\n* Uncontrolled hepatitis B, hepatitis C, or HIV at time of blood collection\n* Taking a disease-modifying drug for AD at time of enrollment\n* Blood transfusion in the last three months\n* Unwilling or unable to participate in all study activities",true,"ALL","60 Years",{"count":119,"type":120},1800,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and predict Alzheimer's disease, which will help to further develop and validate blood tests for the disease.",[124,125,126],"Alzheimer Disease","Mild Cognitive Impairment","Dementia","2026-09-08",{"date":129,"type":130},"2026-09-11","ACTUAL",{"date":132,"type":130},"2024-08-14",{"date":134,"type":120},"2028-12",{"name":5,"class":6},1]